İçeriğe geç
akaturk Akademik ölçüm

Makale detayı · 2021 · article

Could plasma based therapies still be considered in selected cases with atypical hemolytic uremic syndrome?

ISSN0041-4301
YÖKSİS OpenAlex Açık erişim · diamond TR Index
Yıl2021
Atıf3OpenAlex
Yüzdelik%47,6
FWCI0,221,00 = dünya ortalaması
Scopus (SJR)Q3
WoS (JCR)Q4

Veri kaynağı ayrımı

  • YÖKSİSYÖKSİS makale kaydı
  • YÖKSİS dergi adıThe Turkish Journal of Pediatrics
  • Katalog eşleşmesi (ISSN)Turkish Journal of Pediatrics
  • OpenAlexOpenAlex zenginleştirmesi (özet, atıf, konular)
  • Semantic Scholaratıf sayısı (OpenAlex ile birleştirilmez)

Özet

OpenAlex İngilizce

BACKGROUND: Atypical hemolytic uremic syndrome (aHUS) occurs due to defective regulation of the alternative complement pathway (ACP) on vascular endothelial cells. Plasma based therapy (PT) was the mainstay of the treatment for aHUS for many years until the introduction of therapies targeting blockage of the complement system. The aim of this study was to evaluate patients with aHUS who had been treated with plasma based therapies alone. METHODS: The outcomes of seven genetically confirmed aHUS patients (2 girls, 5 males) were evaluated by means of clinical presentation, response to plasma therapy, course of the disease during the follow-up period and last status. RESULTS: The median age of the patients at admission was 6.7 years (IQR 0.7-7.8). Three patients received plasma exchange therapy and the other four patients were treated with plasma infusions. One patient was lost to follow-up after one year; the median duration of follow-up for other patients was 3.7 years (IQR 2.7-6.5). During the follow up, two patients from our historical records when complement blocking therapies had not been in clinical use yet in Turkey, underwent kidney transplantation. One transplant patient experienced an acute rejection episode without graft loss. The remaining five patients had a glomerular filtration rate of more than 90 ml/min./1.73 m < sup > 2 < /sup > at the last visit. CONCLUSION: Although we had a relatively small patient population, our findings indicate that PT might still be considered in selected patients particularly in countries where complement blocking therapies are difficult to reach due to their unavailability or costs that are not covered by the health care systems.

Konular

Atıflar

OpenAlex cited_by_count. WoS veya Scopus atıf sayısı değildir; o kaynaklar için ayrı kolon yoktur.

3atıfOpenAlex · cited_by_count (önbellek / veritabanı)

Yerel katalogda bu makaleye atıf yapan 3 yayın (OpenAlex referans eşleşmesi; tam dünya listesi değildir).

  1. 2024 Management of pediatric hemolytic uremic syndromeAtıf 7 · OpenAlex
  2. 2024 Management of pediatric hemolytic uremic syndromeAtıf 7 · OpenAlex
  3. 2024 Management of pediatric hemolytic uremic syndromeAtıf 7 · OpenAlex

Yazarlar

14
  1. SARE GÜLFEM ÖZLÜ 1
  2. BORA GÜLHAN 2
  3. ÖZLEM AYDOĞ 3
  4. Emine Atayar 4
  5. ALİ DELİBAŞ 5
  6. GÖNÜL PARMAKSIZ 6
  7. ELİF BAHAT ÖZDOĞAN 7
  8. ELİF ÇOMAK 8
  9. MEHMET TAŞDEMİR 9
  10. BANU ACAR 10
  11. ZEYNEP BİRSİN ÖZÇAKAR 11
  12. REZAN TOPALOĞLU 12
  13. HÜSNÜ OĞUZ SÖYLEMEZOĞLU 13
  14. FATİH ÖZALTIN HACETTEPE ÜNİVERSİTESİ 14